**2 April 2020** **Sydney, Australia**

# Updated Noxopharm Virtual Roadshow Corporate Presentation

**Sydney, 2 April 2020:** Noxopharm (ASX: NOX) is pleased to provide shareholders and the market the attached Noxopharm "Updated Non-Deal Roadshow Corporate Presentation".

This updated document is being used by Noxopharm for presentations during a non-deal virtual roadshow being held by the company on 2nd April 2020.

The presentation can be found at www.noxopharm.com

**About Noxopharm**

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder in Nyrada Inc.

www.noxopharm.com

**Investor & Corporate Enquiries:**
Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

**Company Secretary:**
David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

**Media queries:**
Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com

*Graham Kelly, CEO and Chairman of Noxopharm has approved the release of this document to the market.*

**Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks,

uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.


# Noxopharm Limited

Veyonda®

## Updated Non-Deal Roadshow Presentation

NOXOPHARM

ASX: NOX

DISCOVER DEVELOP DELIVER

# Disclaimer

This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

NOXOPHARM

# Contents



NOXOPHARM

**Veyonda®**

# Introduction

**Technology platform**

- isoflavonoid molecular structure offering new generation of therapeutics built around polypharma actions (tyrosine and serine-threonine kinase inhibition) and restriction to prion-like (abnormal functioning) kinase targets

**Proprietary IP**

- structure/functional relationship; delivery technology

**Veyonda®**

- dual cytotoxic/immuno-oncology drug for late-stage prostate cancer
- versatility (polypharma action) demonstrated by ability to block cytokine storm/septic shock

**Drug pipeline**

- oral cytotoxic for pancreatic/gall-bladder cancers
- first-in-class glutamate G-protein receptor inhibitor for GBM

We are a **drug discovery and drug development company**. We will seek strategic partnerships for pipeline drugs when they attain **key valuation points**

NOXOPHARM

# Investment Case

Veyonda® being positioned for the largest sector in the oncology market

- **end-stage cancer where treatment limited to palliative care**
- **little competition**
- **multi-billion $ market opportunity**

Veyonda® immediate goal is late-stage prostate cancer

- **estimated 300,000 p.a. deaths globally**
- **estimated 33,000 in the U.S. in 2020**
- **U.S. market alone estimated at US$1 billion +**

Veyonda® considerably de-risked

- **safety confirmed**
- **evidence of meaningful clinical efficacy in Phase I/II trials**
- **multiple programs (DARRT, LuPIN, CEP, IONIC)**

Commercial outreach commenced

- **GenesisCare relationship**
- **territorial carve-outs being explored**

Lean operation. Virtual company

** American Cancer Society Cancer Statistics Centre 2020*

NOXOPHARM

# COVID-19 Program



- Death due primarily to multi-organ failure associated with abnormally excessive immune and inflammatory responses
- Particularly lung failure from acute respiratory distress syndrome (ARDS)
- Organ failure caused by excessive production of inflammatory proteins known as cytokines
- *Cytokine storm* in COVID-19 patients similar to septic shock in overwhelming infections with bacteria and other viruses including other coronaviruses (SARS, MERS)
- Multiple cytokines involved, notably IL-6 and TNF$\alpha$
- Various companies intending  to conduct clinical trials in China, US, Europe designed to block action of cytokines
- Objectives:
  - To reduce excessive inflammatory response
  - To reduce need for ventilation support
  - To reduce ICU admittance
  - To avoid sepsis, ARDS and multi-organ failure

NOXOPHARM

# COVID-19: rationale for cytokine inhibitors such as IL-6 Inhibitors




Patients with high level of IL-6 are less likely to survive SARS-COV2 (COVID-19) virus infection

**Zhou et al. 11 March 2020. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet https://doi.org/10.1016/ S0140-6736(20)30566-3**

NOXOPHARM

# COVID-19

**Hudson Institute of Medical Research (HIMR)**

- 18-month collaboration with NOX to determine range of immuno-oncology functions of idronoxil
- IL-6 inhibition known and thought to contribute to anti-cancer function
- HIMR discovers idronoxil has broader effects than on IL-6 with potent inhibition of multiple cytokines
- Potential therapeutic use in cytokine storm in septic shock including COVID-19

**Potential advantages of idronoxil in COVID-19 in particular and septic shock generally**

- Range of cytokines inhibited closely matches those involved in *cytokine storm*
- Most other drugs being tested are antibodies directed at single cytokines
- Idronoxil blocks production of cytokines, not just seeks to inhibit their action
- Idronoxil proven to be well-tolerated in over 800 cancer patients to date

NOXOPHARM

# COVID-19 Next Steps



**Funding**

- Company to seek non-dilutive funding. Overseas governments funding a number of trials
- Funding would allow assembly of dedicated COVID-19 team under Dr Mautner and production of sufficient quantities of drug for some thousands of patients

**Clinical study**

- Oral dosage formulation (NOX-19) proposed to be used
- Patients with early-stage symptoms of ARDS and evidence of *cytokine storm*
- Study likely to be conducted in the U.S. and/or Europe. (NB. Veyonda has IND in the U.S.)
- To be determined if formal study or compassionate use

NOXOPHARM

# Clinical Strategy for Prostate Cancer

- Main objective:

To provide a clinical data package that is attractive for future commercial partners

- Implementation Steps:
  - First Prostate Cancer clinical trial (DARRT-1) has finished and was successful
  - Second Prostate Cancer clinical trial (LuPIN-1) is ongoing and showing encouraging interim results
  - Next clinical trial (DARRT-2) will build on these results and will include more patients
  - News flow and a growing data portfolio will be ensured

NOXOPHARM

# Which Market Segment does Veyonda occupy?




NOXOPHARM

# Veyonda® – What does the Clinical Data show?

- 26 men enrolled with late-stage **prostate cancer**
- Metastatic castration-resistant prostate cancer (mCRPC)
- Progressive disease
- No remaining standard treatment options
- Eligible for palliative RT for symptomatic relief

- Treatment with low-dose RT (20Gy in 5 fractions) and 14 days of NOX66 (400, 800, 1200 mg)



Bone scan with metastatic disease

DARRT = Direct and Abscopal Response to Radiation Therapy; RT = Radiation Therapy

NOXOPHARM

# DARRT-1: Does Veyonda work?

- In the 15* patients who were evaluable at 6 months[1]

## The Tumours stopped growing or reduced in size in 10 patients

(1 patient achieved a partial response and 9 achieved stable disease at 6 months)

| 6-months follow up | First part 400mg, 800mg & 1200mg (Reported on 12 November 2019) | Expansion part 1200mg | Overall All doses (Reported on 2 December 2019) |
|---|---|---|---|
| Overall (RECIST1.1) | N=10 | N=5 | N=15 |
| Complete response | 0 | 0 | 0 |
| Partial response | 1 (10%) | 0 | 1 (7%) |
| Stable disease | 7 (70%) | 2 (40%) | 9 (60%) |
| Progressive disease | 2 (20%) | 3 (60%) | 5 (33%) |

** 10 patients lost to follow-up, were not measurable, withdrew from study or died (unrelated to treatment)*

1. Noxopharm. Data on file.

NOXOPHARM

# What is the Aim of the next Trial?

- **Objectives:**
  - **The DARRT-2 trial is designed to provide the data that Commercial Partners are looking for**
  - **It also aims to satisfy the Regulatory Authorities**
- Building on the experience and data of DARRT-1
- Phase 2 trial; multinational
- Medical Advisory Boards established
- Anticipated regulatory submissions late-2020
- Study expected to commence in early-2021

✓ **We are developing the most efficient and impactful study possible**

NOXOPHARM

# Additional Opportunity in Prostate Cancer

## External Radiation

- Standard-of-Care
- Widely used

DARRT

## Internal Radiation

- Experimental
- Billion-dollar Acquisition by Novartis



LuPIN

NOXOPHARM

# LuPIN Trial: Key Interim Results

❖ **Veyonda® + $^{177}$Lu-PSMA-617**

- Overall Survival (OS) is a measure of the time from the start of treatment until death.


✓ Median OS was **17.1 months** – a remarkable result at this late stage of the disease

✓ The combination therapy was well tolerated, pointing to Veyonda® being safe to use in combination with intravenous radiotherapy

***In summary, combination therapy of Veyonda® and $^{177}$Lu-PSMA-617 showed major benefits to patients and underscores the Company's confidence in Veyonda® eventually becoming a standard drug in the management of prostate cancer***

NOXOPHARM

# Commercial Strategy

## Noxopharm commercial priorities

1. Attract potential partners by continuing to undertake clinical trials to develop Veyonda® as standard of care in treatment of prostate cancer → DARRT-2 Phase 2 clinical trial planning underway
2. Develop alliances to strengthen the commerciality of Veyonda® → GenesisCare use of Veyonda® for compassionate treatment
3. Investigate commercial agreements to build revenue prior to commercialisation of Veyonda® → Pursuing regional licencing agreements for Veyonda®
4. Leverage the IP and clinical expertise of Noxopharm in urgent situations → COVID-19 treatment research

NOXOPHARM

# Market Opportunity

## Prostate cancer market opportunity

- 33,330 prostate cancer deaths are forecast in the US in 2020*
- Potentially all of these patients could benefit from treatment with Veyonda®
- The potential global demand of late stage cancer patients for multiple cycles of Veyonda® indicates potential for multi-million dollar revenue from Veyonda®

  → positioning Veyonda® for acquisition by big pharmaceutical companies

## Recent acquisitions in the prostate cancer space

| Recent acquisitions | Buyer | Seller | Price range |
|---|---|---|---|
| **XTANDI® mCRPC (2016)** | Pfizer | MEDIVATION | US$14 billion |
| **$^{177}$Lu-PSMA-617 mCRPC (2018)** | NOVARTIS | ENDOCYTE | US$2.1 billion |
| **$^{177}$Lu-PSMA-617 & others mCRPC (2018)** | NOVARTIS | Advanced Accelerator Applications | US$3.9 billion |

** American Cancer Society Cancer Statistics Centre 2020*

NOXOPHARM

## For further information please visit

## www.noxopharm.com

Veyonda®

NOXOPHARM

ASX: NOX

DISCOVER DEVELOP DELIVER